Iovance 1Q26 net loss narrows to $79.05 million; revenue rises 45% to $71.43 million

Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

IOVA

0.00
  • Iovance Biotherapeutics reported 1Q26 revenue of USD 71.43 million, up about 45% year over year, while net loss narrowed to USD 79.05 million.
  • Operating loss improved to USD 81.04 million; R&D expense fell to USD 62.49 million, down 12% versus 4Q25.
  • Gross margin was 41%, absorbing one-time costs tied to annual maintenance and a recent internal facility expansion.
  • Guided 2Q26 revenue at USD 86 million to USD 88 million; forecast FY26 revenue of USD 350 million to USD 370 million.
  • Interim CEO Frederick Vogt said adoption and commercial expansion for Amtagvi is accelerating after record high demand; company expects manufacturing efficiencies and cost reductions to lift gross margin and support profitability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.